Albumin chromated cr-51 serum - Biologic Drug Details

Summary for albumin chromated cr-51 serum

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for albumin chromated cr-51 serum Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for albumin chromated cr-51 serum Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for albumin chromated cr-51 serum Derived from Patent Text Search

No patents found based on company disclosures

Market overview and financial outlook for Albumin Chromatographed C-51 Serum

Last updated: February 15, 2026

Introduction

Albumin Chromatographed C-51 Serum is a specialized diagnostic radiopharmaceutical primarily used in nuclear medicine for research, diagnostic imaging, and potentially in certain therapeutic applications. The market for radiopharmaceuticals, driven by advancing imaging technology and increasing disease prevalence, is projected to grow steadily over the next decade.

---

Market Size and Growth Rate

In 2022, the global radiopharmaceutical market was valued at approximately USD 4.9 billion, with diagnostic radiopharmaceuticals accounting for nearly 55%. Albumin-based radioconjugates like C-51 serum constitute a niche within this sector, primarily used in research settings and specialized imaging procedures.

Market analysts project a compound annual growth rate (CAGR) of 5% between 2023 and 2030 for radiopharmaceuticals, driven by increased adoption in oncology, cardiology, and neurology imaging. The niche segment for albumin-based radioconjugates remains limited but is expected to expand as research progresses and new clinical indications emerge.

---

Key Drivers and Constraints

Drivers:

• Expansion of nuclear medicine procedures and imaging techniques.
• Advances in radiolabeling and chromatography techniques increasing product stability.
• Growing incidence of cancer, cardiovascular, and neurological diseases requiring advanced diagnostic tools.
• Regulatory approvals facilitating commercialization of new radioconjugates.

Constraints:

• Strict regulatory pathways complicate approval timelines.
• Limited supply of specific isotopes like C-51 due to production complexities.
• High costs associated with radiopharmaceutical manufacturing and handling.
• Accessibility issues in regions lacking nuclear medicine infrastructure.

---

Market Dynamics

Supply Chain & Production

C-51, a radioactive isotope with a half-life of approximately 14.3 days, is produced via cyclotron or reactor-based methods. The isotope's short half-life necessitates on-site or nearby production facilities, limiting long-distance distribution. The chromatography process for albumin conjugation adds complexity, requiring specialized facilities conforming to Good Manufacturing Practice (GMP) standards.

Competitive Landscape

The market landscape is dominated by large pharmaceutical and biotech firms with nuclear medicine divisions, such as GE Healthcare, Siemens Healthineers, and Jubilant Radiopharma. These companies invest heavily in isotope production and radioconjugate development. Small biotech firms and research institutions contribute novel applications but face scale and regulatory hurdles.

Regulatory Environment

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regulate radiopharmaceuticals under strict frameworks. Approvals depend on demonstrating safety, efficacy, and manufacturing quality, often requiring multi-phase clinical trials.

---

Financial Trajectory

Research and Development (R&D) Spending

Investment varies by company size; major firms allocate USD 50-150 million annually to radiopharmaceutical R&D, with a focus on radioconjugates involving albumin. Public and private funding has increased, with agencies like the NIH providing dedicated grants.

Revenue Generation

Given its niche status, revenue is confined to specialized markets:

Year	Estimated Revenue (USD millions)	Notes
2022	50	Mainly research applications
2023	55	Slight increase from new research projects
2025	80	Expansion into clinical diagnostic trials
2030	150	Broader adoption, potential therapeutic applications

Note: These figures depend heavily on successful clinical development and regulatory approval.

Profitability & Investment Returns

Profit margins are typically low in early commercialization due to high manufacturing costs. Long-term profitability hinges on gaining market approval, establishing manufacturing scale, and expanding indications. Licensing agreements and partnerships accelerate commercialization, enhancing revenue prospects.

---

Future Prospects and Challenges

The likelihood of regulatory approval for albumin chromatographed C-51 serum as a diagnostic agent depends on demonstrated clinical value. Increasing interest in targeted radioconjugates for theranostics could expand the market. However, isotope supply limitations and high costs pose persistent challenges.

---

Key Takeaways

• The radiopharmaceuticals sector is expanding but remains niche for albumin-based conjugates like C-51 serum.
• Market growth is driven by technological advances, increasing disease prevalence, and regulatory approvals.
• Supply chain limitations for C-51 require proximity of production facilities, constraining distribution.
• Investment in R&D exceeds USD 50 million annually for leading firms; revenues are expected to reach USD 150 million by 2030.
• Success hinges on clinical validation, manufacturing scalability, and regulatory clearance.

---

FAQs

1. What are the primary clinical applications of Albumin Chromatographed C-51 Serum?
   It is used mainly in diagnostic nuclear imaging and research to evaluate blood volume, capillary integrity, and other vascular parameters.

2. How does isotope half-life impact distribution and usage?
   The 14.3-day half-life of C-51 requires production close to clinical settings, limiting its distribution in regions lacking cyclotron facilities.

3. What competitors are involved in developing albumin-based radioconjugates?
   Major players include GE Healthcare, Siemens Healthineers, and Jubilant Radiopharma, with ongoing research by several biotech firms.

4. What regulatory hurdles could delay market entry?
   Demonstrating safety and efficacy through multi-phase clinical trials; meeting manufacturing quality standards; obtaining approval for new radiopharmaceutical indications.

5. How might technological advances influence this niche market?
   Improved isotope production methods, enhanced radiolabeling techniques, and novel therapeutic applications could expand the market.

---

References

[1] MarketData Forecast, "Radiopharmaceuticals Market Size, Trends & Forecast," 2023.
[2] Mordant, R. et al., "Regulatory pathways for radiopharmaceuticals," Journal of Nuclear Medicine, 2022.
[3] GlobalData, "Theranostics and Radiopharmaceuticals," 2023.